Parmantier & Cie. GmbH

Frankfurt am Main, June 23, 2025 – CLINUVEL Pharmaceuticals Ltd. (ASX: CUV; WKN: AOJEGY) is setting key strategic signals for its next growth phase: Following a full recovery, CEO Dr. Philippe Wolgen has returned to lead the company’s operations and is now driving forward expansion into the North American market. The targeted approval of SCENESSE® for the treatment of vitiligo in the United States and Canada is expected to mark a potential turning point in CLINUVEL’s business model.
At the same time, CLINUVEL is accelerating its presence in the U.S. through targeted M&A activities, aiming to rapidly achieve critical scale in the world’s most important pharmaceutical market. Currently, 104 of 120 treatment centers for EPP patients are active – and are expected to be ready for future use in treating vitiligo patients.
“Dr. Wolgen’s return marks a pivotal moment for CLINUVEL. His strategic vision and the company’s financial strength create the foundation for sustainable growth and a new market position in North America,” said Thomas Schiessle, Analyst at Parmantier & Cie. Research.
With a strong balance sheet, high liquidity, and a defensive core business focused on EPP treatment, CLINUVEL is well-positioned. Analysts at Parmantier & Cie. confirm their target price of AUD 22.00 and reiterate a Buy recommendation, with upside potential of +126% relative to the current share price.
Further positive impulses could arise from European regulators – particularly through the planned extension of SCENESSE® approval to adolescent EPP patients and unified treatment guidance from the EMA.
Full research report available at:
Bloomberg ; FactSet ; LSEG
Online: https://www.parmantiercie.com/research
About PARMANTIER & CIE. GmbH
PARMANTIER & CIE. is a modern merchant bank based in Frankfurt am Main. The firm advises companies on all aspects of financing – equity, debt, and hybrid instruments – and also invests its own capital in listed and private companies. PARMANTIER & CIE. stands for integrity, foresight, and tailored financing solutions with entrepreneurial commitment.
Contact for further inquiries:
Parmantier & Cie. Research
Hungener Straße 6
60389 Frankfurt am Main
E-mail: info@parmantiercie.com